Going with the flow, and beyond, in myeloma
Open Access
- 15 November 2008
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 112 (10), 3917-3918
- https://doi.org/10.1182/blood-2008-08-175026
Abstract
In this issue of Blood, Paiva and colleagues report that MFC performed on bone marrow examinations on day 100 after autotransplantation and intended to provide a measure of MRD in multiple myeloma distinguished patients with strikingly different progression-free and overall survival, independent of standard baseline prognostic variables and IFx-defined CR.Keywords
This publication has 9 references indexed in Scilit:
- Making progress in treating multiple myeloma with total therapies: issue of complete remission and moreLeukemia, 2008
- Role of autologous stem-cell transplantation in multiple myelomaBest Practice & Research Clinical Haematology, 2007
- New Drugs for MyelomaThe Oncologist, 2007
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical ImplicationsJournal of Clinical Oncology, 2007
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2006
- The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple MyelomaNew England Journal of Medicine, 2003
- Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma.2000
- Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myelomaBlood, 2000